Immunization Updates 2023: From COVID to Chickenpox
In this course, participants will gain a thorough understanding of contraindications and precautions, ensuring the safe administration of vaccines
About this webinar
In today’s rapidly evolving landscape of infectious diseases, healthcare professionals face an urgent need to stay updated on crucial vaccine recommendations. This 2-hour continuing education program addresses this pressing demand by providing comprehensive insights into immunization strategies. Focused on the Immunization Schedules set by the Advisory Committee on Immunization Practices (ACIP), the course covers essential aspects such as COVID-19 vaccine formulations, updates on authorized vaccines, and preventive measures for varicella, pneumococcus, and hepatitis.In this course, participants will gain a thorough understanding of contraindications and precautions, ensuring the safe administration of vaccines. By strengthening defenses against infectious diseases through education and action, participants become adept advocates for immunization, driving positive change and securing a brighter future for public health.
At the conclusion of this continuing education activity, the participant will be able to:
Discuss how approved COVID vaccines work with the immune system to stimulate a protective and lasting (memory) immune response
Provide current recommendations for COVID-19 vaccination
Describe recent updates on administration of vaccines to prevent hepatitis A and B, varicella and other infectious diseases
Explain potential contraindications and precautions for vaccines
Instructors
Aimee Bernard, PhD is an Assistant Professor in the Department of Immunology and Microbiology at the University of Colorado Anschutz medical campus and teaches immunology within the graduate school, medical school, dental school, and the Physician Assistant program. Aimee is also the Assistant Director for the CU Human Immunology and Immunotherapy Initiative (HI3), which is focused on the discovery and use of human immunotherapies for the treatment of cancer and a range of other diseases. Aimee has a broad background in cellular immunology and molecular biology, having attained her PhD studying the developmental regulation of human B cells and Systemic Lupus Erythematosus. Aimee received her BA from Gustavus Adolphus College and her PhD from the University of Rochester.
Stephanie James, PhD, MBA earned her undergraduate degree in Biology from Gonzaga University, her MS degree in Biology from Eastern Washington University and an MBA from the City University of Seattle. After spending years in the biotechnology industry, she returned to school at the University of Northern Colorado earning her doctoral degree in Biological Education, studying both education and zoonotic viruses, completing her dissertation on “The Effects of TGF on Hantavirus Cardiopulmonary Disease”. Following her graduate studies, she completed a postdoctoral fellowship in the Department of Neurology at the University of Colorado where her research investigated the immune responses to Varicella zoster virus reactivation (which causes shingles).